Tezspire heart safety study
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at whether the asthma medicine Tezspire (tezepelumab) affects the risk of heart problems compared to other standard treatments for severe asthma. It will help doctors understand if Tezspire is safe for your heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of asthma and are taking Tezspire or another strong asthma treatment for severe asthma.
- You are 12 years old or older.
- You do not have a history of congenital heart disease or a heart transplant.
- You have not had a heart attack or stroke in the last 6 months.
- For comparison, you haven't taken other biologic drugs for asthma recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called tezepelumab for people with severe asthma that is not well controlled with current treatments. It aims to see if adding this drug can reduce asthma attacks and improve symptoms.
This trial tests a new medicine, QL2302, to see how well it works compared to an approved treatment called Tezspire for people with severe asthma. If you have asthma that is not well controlled despite using daily inhalers and other medications, you may be able to join.
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
This trial tests if a drug called Tezepelumab can help adults with asthma who visit the emergency room. It aims to reduce severe asthma attacks and improve breathing control.
This study tests whether a physical activity program can help people with severe asthma achieve better control and reduce flare-ups when added to a new treatment called tezepelumab.
This trial tests tezepelumab, an injected medication, for people with moderate to very severe COPD who still have flare-ups despite using standard inhalers. It may help reduce flare-ups and improve breathing for those with higher eosinophil levels.
Hear when a new Cardiovascular Events trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.